Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIFC NASDAQ:ENGN NASDAQ:KLRS NASDAQ:LITS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.64-11.5%$0.94$0.63▼$10.95$88.89M1.711.46 million shs2.26 million shsENGNenGene$1.64-4.7%$4.91$1.40▼$12.25$109.86M-0.32.81 million shs952,721 shsKLRSKalaris Therapeutics$4.44-4.7%$5.50$2.14▼$11.88$105.64M0.1582,088 shs140,751 shsLITSLite Strategy$0.75-13.4%$1.11$0.70▼$9.00$25.48M0.21548,945 shs837,075 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma-11.45%-25.30%-33.08%-53.93%-93.47%ENGNenGene-4.65%-11.35%-81.47%-81.11%-57.18%KLRSKalaris Therapeutics-4.72%-15.75%-12.25%-54.79%+43.69%LITSLite Strategy-13.35%-25.86%-37.08%-34.32%+74,879,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.64-11.5%$0.94$0.63▼$10.95$88.89M1.711.46 million shs2.26 million shsENGNenGene$1.64-4.7%$4.91$1.40▼$12.25$109.86M-0.32.81 million shs952,721 shsKLRSKalaris Therapeutics$4.44-4.7%$5.50$2.14▼$11.88$105.64M0.1582,088 shs140,751 shsLITSLite Strategy$0.75-13.4%$1.11$0.70▼$9.00$25.48M0.21548,945 shs837,075 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma-11.45%-25.30%-33.08%-53.93%-93.47%ENGNenGene-4.65%-11.35%-81.47%-81.11%-57.18%KLRSKalaris Therapeutics-4.72%-15.75%-12.25%-54.79%+43.69%LITSLite Strategy-13.35%-25.86%-37.08%-34.32%+74,879,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIFCALT5 Sigma 1.00SellN/AN/AENGNenGene 2.21Hold$12.68673.28% UpsideKLRSKalaris Therapeutics 2.75Moderate Buy$15.60251.35% UpsideLITSLite Strategy 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest LITS, ENGN, AIFC, and KLRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026LITSLite Strategy Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/15/2026ENGNenGene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026ENGNenGene UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$9.00 ➝ $2.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/13/2026KLRSKalaris Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/13/2026KLRSKalaris Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$26.00 ➝ $25.005/8/2026ENGNenGene Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$4.005/8/2026ENGNenGene Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$7.00 ➝ $4.005/8/2026ENGNenGene CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeMarket Outperform ➝ Market Perform5/8/2026ENGNenGene Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$25.00 ➝ $2.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIFCALT5 Sigma$24.84M3.58N/AN/A$9.07 per share0.07ENGNenGeneN/AN/AN/AN/A$2.60 per shareN/AKLRSKalaris TherapeuticsN/AN/AN/AN/A$4.21 per shareN/ALITSLite Strategy$65.30M0.39$5.35 per share0.14$4.96 per share0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIFCALT5 Sigma-$344.51MN/AN/AN/AN/A-2,483.94%-68.25%-62.43%N/AENGNenGene-$117.30M-$2.25N/AN/AN/AN/A-55.83%-45.74%6/11/2026 (Estimated)KLRSKalaris Therapeutics-$43.44M-$2.15N/AN/AN/AN/A-72.78%-43.49%N/ALITSLite Strategy-$15.94M-$1.60N/AN/AN/AN/A-90.81%-89.33%N/ALatest LITS, ENGN, AIFC, and KLRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/11/2026Q2 2026ENGNenGene-$0.48N/AN/AN/AN/AN/A5/18/2026Q1 2026AIFCALT5 SigmaN/A-$2.14N/A-$2.14N/A$4.71 million5/13/2026Q3 2026LITSLite StrategyN/A-$0.66N/A-$0.66N/AN/A5/12/2026Q1 2026KLRSKalaris Therapeutics-$0.52-$0.46+$0.06-$0.46N/AN/A4/11/2026Q4 2025AIFCALT5 SigmaN/A-$6.19N/A-$6.19N/A$5.37 million3/17/2026Q4 2025KLRSKalaris Therapeutics-$0.56-$0.44+$0.12-$0.44N/AN/A3/9/2026Q1 2026ENGNenGene-$0.55-$0.44+$0.11-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIFCALT5 SigmaN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/ALITSLite StrategyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIFCALT5 Sigma0.030.820.82ENGNenGene0.0911.7511.75KLRSKalaris TherapeuticsN/A12.1912.19LITSLite StrategyN/A11.5311.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIFCALT5 Sigma6.27%ENGNenGene64.16%KLRSKalaris Therapeutics66.05%LITSLite Strategy52.38%Insider OwnershipCompanyInsider OwnershipAIFCALT5 Sigma0.21%ENGNenGene10.50%KLRSKalaris Therapeutics68.10%LITSLite Strategy1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIFCALT5 Sigma170139.84 million139.54 millionN/AENGNenGene3166.99 million59.95 millionN/AKLRSKalaris Therapeutics11023.79 million7.59 millionN/ALITSLite Strategy10034.03 million33.48 millionN/ALITS, ENGN, AIFC, and KLRS HeadlinesRecent News About These CompaniesLite Strategy, Inc. Common Stock (LITS) SEC FilingsMay 20, 2026 | nasdaq.comLite Strategy Reports Fiscal 2026 Third Quarter ResultsMay 13, 2026 | globenewswire.comIs Lite Strategy (NASDAQ:LITS) In A Good Position To Invest In Growth?April 25, 2026 | finance.yahoo.comLite Strategy Inc.April 18, 2026 | barrons.comLite Strategy IncApril 8, 2026 | cnn.comLite Strategy, Inc. Common Stock (LITS) Institutional HoldingsApril 6, 2026 | nasdaq.comLite Strategy Inc LITSMarch 26, 2026 | morningstar.comMLite Strategy, Inc. Reports Second Quarter Fiscal 2026 Financial Results and Launches Active Treasury Management InitiativesFebruary 17, 2026 | quiverquant.comQLite Strategy Reports Fiscal 2026 Second Quarter ResultsFebruary 17, 2026 | globenewswire.comLiTHOS Announces Board and Management ChangeJanuary 14, 2026 | newsfilecorp.comNJames Flynn Acquires 70,000 Shares of Lite Strategy (NASDAQ:LITS) StockDecember 23, 2025 | insidertrades.comFive Days, Zero Inflows: Litecoin ETF Struggles to Break $7.44 MillionNovember 25, 2025 | finance.yahoo.comLite Strategy names acting CEO Justin File to role on a permanent basisNovember 20, 2025 | msn.comLite Strategy Reports First Quarter Fiscal Year 2026 Results, Highlights Successful Launch of $100 Million Litecoin Treasury Strategy and Movement Into Active Capital Market ...November 18, 2025 | dailyhodl.comDLite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market OperationsNovember 17, 2025 | markets.businessinsider.comLite Strategy $25M Share RepurchaseOctober 30, 2025 | ventureburn.comVLite Strategy announces $25M share repurchase programOctober 29, 2025 | msn.comLite Strategy stock surges after announcing $25 million share buybackOctober 29, 2025 | in.investing.comLite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market OperationsOctober 29, 2025 | markets.businessinsider.comLite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026October 16, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLITS, ENGN, AIFC, and KLRS Company DescriptionsALT5 Sigma NASDAQ:AIFC$0.64 -0.08 (-11.45%) As of 06/5/2026 04:00 PM EasternALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.enGene NASDAQ:ENGN$1.64 -0.08 (-4.65%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.62 -0.02 (-1.22%) As of 06/5/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Kalaris Therapeutics NASDAQ:KLRS$4.44 -0.22 (-4.72%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$4.33 -0.11 (-2.57%) As of 06/5/2026 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Lite Strategy NASDAQ:LITS$0.75 -0.12 (-13.35%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.76 +0.01 (+1.90%) As of 06/5/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
